← Back to Search

[18F]MNI-444 for Healthy Subjects

Phase 1
Waitlist Available
Led By David Russell, M.D., Ph.D
Research Sponsored by Invicro
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing if caffeine can help prevent Parkinson's by binding to receptors in the brain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the pharmacodynamics of multiple doses of oral caffeine on striatal binding of the adenosine A2A receptor ligand [18F]MNI-444.
To evaluate the pharmacokinetics of multiple doses of oral caffeine on striatal binding of the adenosine A2A receptor ligand [18F]MNI-444.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]MNI-444Experimental Treatment1 Intervention
After a wash-out of caffeine of at least 24 hours, each participant will receive a single injection of [18F]MNI-444 followed by brain PET imaging of up to 90 minutes to establish baseline A2A receptor binding.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]MNI-444
2021
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

InvicroLead Sponsor
16 Previous Clinical Trials
382 Total Patients Enrolled
David Russell, M.D., Ph.DPrincipal InvestigatorInvicro
1 Previous Clinical Trials
130 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
2021. "Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05009199.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top